Moleculin Biotech, Inc. (MBRX) stock
MBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.87−0.19 (-2.36%)
Close on Nov 13, 2026Market cap $8.23MP/E –Yield –
Moleculin Biotech r&d expenses
Research and development expenses are spending on new products and technology.
Moleculin Biotech's R&D Expenses for the twelve months ending Sep 30, 2026 was $20.43M, up 34.2% year over year. For fiscal 2025 it was $15.89M, down 10.4% from the year before. The highest annual figure on record is $19.49M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.89M | -10.4% |
| FY2024 | Dec 31, 2024 | $17.73M | -9.0% |
| FY2023 | Dec 31, 2023 | $19.49M | +2.7% |
| FY2022 | Dec 31, 2022 | $18.97M | +31.6% |
| FY2021 | Dec 31, 2021 | $14.42M | +13.0% |
| FY2020 | Dec 31, 2020 | $12.76M | +15.8% |
| FY2019 | Dec 31, 2019 | $11.01M | +13.2% |
| FY2018 | Dec 31, 2018 | $9.73M | +114.0% |
| FY2017 | Dec 31, 2017 | $4.55M | +203.8% |
| FY2016 | Dec 31, 2016 | $1.50M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.49M | +20.1% |
| Q2 FY2026 | Jun 30, 2026 | $5.45M | +51.4% |
| Q1 FY2026 | Mar 31, 2026 | $5.38M | +56.6% |
| Q4 FY2025 | Dec 31, 2025 | $5.12M | +14.9% |
| Q3 FY2025 | Sep 30, 2025 | $3.74M | -24.2% |
| Q2 FY2025 | Jun 30, 2025 | $3.60M | -12.0% |
| Q1 FY2025 | Mar 31, 2025 | $3.44M | -19.2% |
| Q4 FY2024 | Dec 31, 2024 | $4.46M | -32.8% |
| Q3 FY2024 | Sep 30, 2024 | $4.93M | +50.4% |
| Q2 FY2024 | Jun 30, 2024 | $4.09M | +5.2% |
| Q1 FY2024 | Mar 31, 2024 | $4.25M | -25.2% |
| Q4 FY2023 | Dec 31, 2023 | $6.63M | +58.7% |
| Q3 FY2023 | Sep 30, 2023 | $3.28M | -45.0% |
| Q2 FY2023 | Jun 30, 2023 | $3.89M | -7.5% |
| Q1 FY2023 | Mar 31, 2023 | $5.69M | +23.1% |
| Q4 FY2022 | Dec 31, 2022 | $4.18M | +31.4% |
| Q3 FY2022 | Sep 30, 2022 | $5.97M | +45.7% |
| Q2 FY2022 | Jun 30, 2022 | $4.20M | +38.3% |
| Q1 FY2022 | Mar 31, 2022 | $4.62M | +12.5% |
| Q4 FY2021 | Dec 31, 2021 | $3.18M | +78.0% |
| Q3 FY2021 | Sep 30, 2021 | $4.10M | -7.7% |
| Q2 FY2021 | Jun 30, 2021 | $3.04M | -8.7% |
| Q1 FY2021 | Mar 31, 2021 | $4.11M | +28.0% |
| Q4 FY2020 | Dec 31, 2020 | $1.79M | -44.1% |
| Q3 FY2020 | Sep 30, 2020 | $4.44M | +59.2% |
| Q2 FY2020 | Jun 30, 2020 | $3.33M | +58.6% |
| Q1 FY2020 | Mar 31, 2020 | $3.21M | +9.3% |
| Q4 FY2019 | Dec 31, 2019 | $3.20M | +9.2% |
| Q3 FY2019 | Sep 30, 2019 | $2.79M | +109.1% |
| Q2 FY2019 | Jun 30, 2019 | $2.10M | -50.4% |
| Q1 FY2019 | Mar 31, 2019 | $2.93M | +137.0% |
| Q4 FY2018 | Dec 31, 2018 | $2.93M | +28.1% |
| Q3 FY2018 | Sep 30, 2018 | $1.33M | +25.5% |
| Q2 FY2018 | Jun 30, 2018 | $4.23M | +380.8% |
| Q1 FY2018 | Mar 31, 2018 | $1.24M | +148.9% |
| Q4 FY2017 | Dec 31, 2017 | $2.29M | – |
| Q3 FY2017 | Sep 30, 2017 | $1.06M | – |
| Q4 FY2016 | Dec 31, 2016 | $880.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $497.00K | – |
See a number that looks wrong?